49 results about "Resistant organism" patented technology

This invention relates to a 1,3,4-thiadiazole peptide deformylase inhibitor and its preparation and application. The structural formula is shown in formula (1): wherein, R 1 It is n-butyl or cyclopentylmethyl; R 2 The compounds are hydrogen-containing, straight-chain alkanes, cyclic alkanes, aromatic rings, substituted biphenyls, or heterocyclic rings. The 1,3,4-thiadiazole peptide deformylase inhibitors provided by this invention can effectively inhibit bacterial protein synthesis, thereby achieving sterilization. These compounds exhibit excellent inhibitory activity against Gram-positive drug-resistant bacteria, especially the clinically challenging methicillin-resistant Staphylococcus aureus (MRSA). In particular, some preferred compounds show inhibitory activity 4-8 times that of the control standards vancomycin and linezolid. The 1,3,4-thiadiazole peptide deformylase inhibitors provided by this invention also exhibit inhibitory activity against Gram-negative drug-resistant bacteria, especially against drug-resistant Acinetobacter baumannii, known as "superbugs," with an inhibitory activity reaching 0.5 μg / mL, far superior to vancomycin and linezolid.

This invention relates to a method for preparing medical nanozymes, the medical nanozymes themselves, their applications, and pharmaceuticals, belonging to the field of biomedicine. It addresses at least one of the following problems in existing technologies for treating deep tissue infections caused by drug-resistant bacteria: poor antibacterial and anti-biofilm effects, insufficient deep tissue penetration, lack of inflammation regulation and tissue repair functions, biosafety risks, and high material preparation costs. The preparation method includes: mixing rhodium trichloride, urea, and polyvinylpyrrolidone to obtain a mixture; subjecting the mixture to staged pyrolysis under inert gas protection to obtain a nitrogen-doped carbon-supported single-atom rhodium catalyst; and modifying the nitrogen-doped carbon-supported single-atom rhodium catalyst with polyethylene glycol. The medical nanozymes prepared by this invention achieve excellent antibacterial and anti-biofilm effects both in vivo and in vitro, can regulate the inflammatory microenvironment, promote tissue repair, exhibit good biocompatibility, and have strong tissue penetration ability.

The application discloses a complex preparation containing bovine lactoferrin and lyticase and application thereof, and belongs to the technical field of biology. The preparation is composed of bovine lactoferrin and streptococcal lyticase, and both are prepared through a baculovirus-insect cell eukaryotic expression system. Researches show that the complex preparation has a significant synergistic antibacterial effect. The complex preparation not only can effectively inhibit a plurality of gram-positive bacteria, but also can overcome the limitation that single streptococcal lyticase has weak activity on gram-negative bacteria, and significantly enhances the inhibiting effect on escherichia coli and salmonella. Especially, the complex preparation still has clear in-vitro antibacterial activity on multi-drug resistant escherichia coli such as ciprofloxacin and doxycycline, thereby providing a new way for developing a new type of drug for resisting drug-resistant bacteria.

This invention discloses a method for preparing selenium-cuprous oxide-lithium saponite composite nanozymes from plant-derived complexes and their antibacterial applications, belonging to the fields of nanomaterials technology and antibacterial agents. The method includes the following steps: using peeled lithium saponite as a carrier, and utilizing a plant-derived complex formed from quinoa husk extract, aloe-emodin, and ascorbic acid as a reducing agent and stabilizer, the selenium-cuprous oxide-lithium saponite composite nanozyme is synthesized. The resulting composite nanozyme has a core-shell structure, with lithium saponite nanosheets as a carrier and uniformly distributed selenium-cuprous oxide nanoparticles on the surface. It exhibits excellent peroxidase-mimicking activity, catalyzing the generation of a large number of reactive oxygen species and disrupting bacterial cell structure. It shows significant antibacterial effects against various drug-resistant bacteria, and possesses good biocompatibility and environmental friendliness, showing broad application prospects in antibacterial therapy, wound dressings, and biomedical engineering.

The application discloses a chimeric endolysin Lys009-Lys009CBD and engineering and application thereof, and belongs to the field of genetic engineering and protein engineering. The application constructs a chimeric endolysin Lys009-Lys009CBD with high activity, and the peptidoglycan hydrolysis activity of the chimeric endolysin Lys009-Lys009CBD on Pseudomonas aeruginosa is 5.30 times that of natural endolysin Lys009 and 27.98 times that of hen egg white lysozyme HEWL. A transmembrane peptide P81417 is further fused to perform transmembrane modification, and an engineering endolysin P81417-Lys009-Lys009CBD is obtained. The engineering endolysin can efficiently lyse Pseudomonas aeruginosa, Acinetobacter baumannii and the like, and has excellent thermal stability. The application enriches the resource library of high-activity endolysins, provides important experimental basis and technical support for developing an anti-drug-resistant bacteria treatment strategy, and also provides a new selection for clinical treatment of multiple drug-resistant bacteria infection.

This invention relates to an oxobenzohexacyclic borate ester compound, its preparation method, and its uses, belonging to the pharmaceutical field. The derivatives of this invention are compounds represented by Formula I, or their salts, conformational isomers, or optical isomers. The oxobenzohexacyclic borate ester derivatives provided by this invention exhibit good, broad-spectrum inhibitory activity against clinically common metallo-β-lactamases (MBL) and serine β-lactamases (SBL), and show good antibacterial activity against various drug-resistant bacteria when used in combination with the β-lactam antibiotic meropenem. Therefore, the series of derivatives provided by this invention have great potential in the preparation of dual broad-spectrum inhibitors of MBL and SBL and in drugs to overcome β-lactam antibiotic-resistant bacteria. Formula I.

This invention discloses the application of the bacterial fission protein FtsZ inhibitor DB1 in the preparation of drugs against drug-resistant bacteria, belonging to the field of drug development technology. The inhibitor provided by this invention is compound DB1, named 3-(2,8-dibromo-10,11-dihydro-5H-dibenzo[b,f]azapheno-5-yl)-N,N-dimethylpropylamine hydrochloride, with the molecular formula C2. 19 H 24 Br2ClN2. This compound, DB1, exhibits significant inhibitory effects against various drug-resistant bacteria, particularly vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus (MRSA), and can significantly improve the susceptibility of methicillin to MRSA. The discovery of compound DB1 provides new ideas and technical support for the preparation of drugs against drug-resistant bacteria.

This invention belongs to the field of peptide drugs, specifically relating to an anti-drug-resistant bacterial peptide and its application in pharmaceutical manufacturing. Using Rink amide MBHA amino resin as a solid-phase support, the amino acid sequence of the template peptide raniseptin PL:Ac-GVFDTVKKIGKAVGKFALGVAKNYLNS-NH2 was modified, with amino acid residues 9I and 16F replaced by R8 and S5, respectively, to obtain the target stapling peptide PL-11. Compared to the template peptide PL-0, the stapling peptide PL-11 significantly enhances the antibacterial activity against Staphylococcus aureus, Enterococcus faecalis, and Staphylococcus epidermidis.

This invention belongs to the field of peptide drugs, specifically relating to an anti-drug-resistant bacterial peptide and its application in pharmaceutical manufacturing. Using Rink amide MBHA amino resin as a solid-phase support, the amino acid sequence of the template peptide raniseptin PL:Ac-GVFDTVKKIGKAVGKFALGVAKNYLNS-NH2 was modified, with amino acid residues 6V and 13V replaced by R8 and S5, respectively, to obtain the target stapling peptide PL-10. Compared to the template peptide PL-0, the stapling peptide PL-10 significantly enhances the antibacterial activity against Staphylococcus aureus, Enterococcus faecalis, and Staphylococcus epidermidis.

This invention discloses the application of an electrode material for reducing intracellular resistance genes in drug-resistant bacteria. A platinum-doped dendritic TiO2 nanowire structure based on a three-dimensional material is formed by growing a micron-sized TiO2 backbone array and platinum-doped nano-sized TiO2 branches on the surface of a porous electrode. The prepared dendritic nanowire three-dimensional electrode material has a larger specific surface area, providing more reactive sites and strong electric field sites. Platinum doping enhances the conductivity and electrocatalytic performance of the nanowires. Furthermore, by combining it with chloride salts / oxidants, the electroporation and electrocatalysis of the nanowire electrode surface are coupled. The strong electric field confined at the nanowire tip induces perforation of the drug-resistant bacterial cell structure, strengthening the contact and reaction between the oxidant and the resistance gene. The high electrocatalytic activity confined at the nanowire tip induces the generation of strong oxidizing free radicals, achieving the goal of destroying the drug-resistant bacterial cell structure and efficiently reducing intracellular resistance genes.

The utility model relates to medical instrument technical field, concretely provides a multiple drug resistant bacteria infusion support, aims at solving the problem of easy to appear the mark error among the existing static multiple drug resistant bacteria visual warning measure. For this purpose, the utility model provides a multiple drug resistant bacteria infusion support, and the multiple drug resistant bacteria infusion support includes: the frame body, mobile device is set up on the frame body, and mobile device is provided with scanning camera, and scanning camera is used for scanning patient identification to obtain identification information, the display is set up on the frame body, and the display is used for at least showing the multiple drug resistant bacteria kind information of patient, first treater is connected with mobile device and the display respectively, and first treater is used for processing identification information to at least obtain the multiple drug resistant bacteria kind information of patient, and make the display at least show the multiple drug resistant bacteria kind information of patient. The utility model solves the problem of easy to appear the mark error among the existing multiple drug resistant bacteria visual warning measure through above -mentioned measure.

This invention provides a permeable photocatalytic nano-antibacterial agent, its preparation method, and its application. The agent uses graphitic carbon nitride nanosheets as the core, with a molecular weight of 10 encapsulated on their surface. 3 ~10 7 The hyaluronic acid nanoparticles form nanostructures with a particle size of 200-400 nm. The nano-graphite phase carbon nitride, with its sharp-edged, sheet-like structure, can physically disrupt drug-resistant bacterial biofilms. Hyaluronic acid enhances the stability of the nano-antibacterial agent in the physiological environment and is degraded by hyaluronidase within the drug-resistant bacterial biofilm, thus disrupting the biofilm's structural stability and promoting efficient penetration and accumulation of the antibacterial agent within the biofilm. Under laser irradiation, the nano-graphite phase carbon nitride catalyzes the generation of reactive oxygen species, synergistically achieving efficient biofilm removal. This nano-antibacterial agent possesses excellent solution stability, biosafety, and photocatalytic activity, making it suitable for treating diseases related to drug-resistant bacterial biofilm infections.

The disclosure is directed to new crystalline tebipenem pivoxil salt forms, including a crystalline tebipenem pivoxil ethane sulfonate salt form (Form A), a crystalline tebipenem pivoxil ketoglutarate salt form (Form A), tebipenem pivoxil maleate salt forms (Form A and Form B), a tebipenem pivoxil malate salt form (Form A), a tebipenem pivoxil methane sulfonate salt form (Form B), a tebipenem pivoxil hydrobromide salt form (Form B), and a tebipenem pivoxil edisylate salt form (Form A). The disclosure also includes a composition, comprising a crystalline tebipenem pivoxil salt and a pharmaceutically acceptable carrier and further includes a method for treating an antibiotic resistant bacterial infection, comprising administering to a patient in need of such treatment a therapeutically effective amount of a crystalline tebipenem pivoxil salt.

The application discloses application of BMS-833923 and derivatives thereof and a medicine, and belongs to the technical field of antibiotics. The BMS-833923 and the derivatives thereof can be used as colistin adjuvants to jointly inhibit or eliminate gram-negative bacteria, and can also independently inhibit or eliminate gram-positive bacteria. The gram-negative bacteria can include at least one of Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, pan-drug-resistant strains BAA-1800, BAA-1794 and BAA-1792, and the gram-positive bacteria can include at least one of Staphylococcus aureus and Bacillus subtilis. By taking the BMS-833923 and the derivatives thereof as adjuvants of colistin, the therapeutic index of the colistin can be effectively expanded, and lower, non-toxic doses of the colistin can be used in clinical treatment of effective treatment of drug-resistant bacterial infections.

The application discloses a synergistic bactericidal composition, comprising the following components: a toona sinensis extract: 16-2048 mu g / mL; a macrolide antibiotic: 0.0625-4096 mu g / mL; the bacteria are staphylococcus aureus or methicillin-resistant staphylococcus aureus, and the macrolide antibiotic is erythromycin or azithromycin. The application further discloses a use of the synergistic bactericidal composition in preparation of a medicine for treating skin and soft tissue infections. The composition provided by the application can convert the traditional macrolide antibiotics such as erythromycin and azithromycin which only have a bacteriostatic effect into a preparation which has clear bactericidal activity on staphylococcus aureus and drug-resistant strains thereof. After the toona sinensis extract is combined with the antibiotic, a synergistic effect is exhibited, and the concentration of the toona sinensis extract and the antibiotic required when the toona sinensis extract and the antibiotic are used alone can be greatly reduced.

This invention discloses an endophytic fungus of *Aspergillus sp.* and its applications. The invention provides a novel endophytic fungus, PS4, which possesses unique antibacterial and antitumor activities. The secondary metabolites produced during fermentation contain various active ingredients, such as shikonin, 10-hydroxycamptothecin, and rhodioloside, exhibiting significant antioxidant, antibacterial, and antitumor effects. Simultaneously, the controllable fermentation process of the endophytic fungus improves the stability and yield of the product. The use of bio-fermentation is more environmentally friendly, reducing environmental impact, and ultimately provides a new option for clinical treatment, especially in combating drug-resistant strains and antitumor drugs.

This invention belongs to the field of antibacterial nanomaterials, specifically relating to nanoparticles that inhibit methicillin-resistant Staphylococcus aureus (MRSA) resistance. The nanoparticles have a three-layer structure, consisting of a core layer composed of a copper nanoparticle and a copper oxide composite, a mesoporous graphite shell, and a bis(amino)PEG coating, from the inside out. The above method achieves physical encapsulation of copper nanoparticles by graphite using a one-step plasma arc method; and constructs a Cu / Cu₂O interface through precise oxygen-controlled thermal oxidation treatment, while simultaneously achieving effective protection and exposure of the active A layer by mesoporousizing the graphite; the use of bis(amino)PEG to form a polymer coating on the nanoparticles enhances bacterial uptake capacity and improves biocompatibility. The nanoparticles prepared by this invention can increase the utilization rate of drug-resistant bacteria by inhibiting bacterial biofilm structures and efflux pumps that cause bacterial infections, thereby improving the clearance capacity against drug-resistant bacterial infections and demonstrating great potential for application and clinical translation.

This utility model relates to the field of animal experimental devices and discloses an isolation tray for drug-resistant bacteria in animals. The tray includes a main body, a fixed frame fixedly connected to the outer wall of the main body, a cover snapped onto the top of the main body, rotating seats fixedly connected to both ends of the cover, and buckles rotatably connected to the outer walls of the rotating seats. A lower box is snapped onto the inner wall of the main body, an upper box is positioned at the top of the lower box, partitions are fixedly connected to the left and right sides of the inner wall of the upper box, a retaining ring is connected to the middle of the inner wall of the upper box via a replaceable component, and a storage component is located on the right side of the inner wall of the upper box. In this utility model, the lower box can collect waste generated during the experiment, which is then shielded by the upper box to form a sealed space. The cover then snaps onto the main body of the isolation tray, creating a double-sealed structure with good isolation effect, preventing waste leakage from the main body of the isolation tray and thus avoiding infection.

The application discloses an intelligent responsive composite hydrogel dressing and a preparation method and application thereof, and belongs to the field of biomedical materials. The preparation method comprises the following steps: preparing arginine grafted quaternary ammonium chitosan LQ; preparing phenylboronic acid functionalized oxidized sodium alginate P-OSA; preparing a multifunctional nanoenzyme complex PMZG; mixing polyvinyl alcohol, LQ, honeysuckle extract and / or PMZG, and then cross-linking with a P-OSA solution to obtain a hydrogel. Through progressive modular design, the hydrogel is endowed with injectability, self-healing, multiple microenvironment responsiveness and cascade catalytic antibacterial, photothermal therapy and pro-angiogenesis capabilities, and can be used for synergistically treating chronic infected wounds, diabetic foot ulcers and drug-resistant bacterial infection wounds, and has a wide clinical application prospect.

This application belongs to the field of antibacterial pharmaceutical technology, specifically relating to a ruthenium-pyridine complex modified with bisimidazole, its preparation method, and its application. The structure of the bisimidazole-modified ruthenium-pyridine complex is shown in Formula I. This invention modifies the electron cloud distribution and targeting by introducing a bisimidazole group into the ruthenium polypyridine ligand. Utilizing the nucleophilic binding properties of bisimidazole and the spatial synergistic effect of the polypyridine ligand, it significantly enhances the interaction between bisimidazole and bacterial cell membrane phospholipids and virulence factors, thereby improving antibacterial activity and anti-biofilm properties, providing a new approach for developing novel and highly effective drugs against drug-resistant bacteria.

The application discloses a photo-activated antibacterial agent semi-amine compound and a preparation method and application thereof, and belongs to the technical field of organic synthesis chemistry. In view of the technical problems of poor stability of semi-amine compounds in the prior art, unexplored biological activity, limited selection of clinical drugs for resisting MRSA and other drug-resistant bacteria and the like, the application realizes a double breakthrough of semi-amine compounds in stability and biological activity by innovatively modifying a traditional coumarin structure. In addition, the application also provides a preparation method and spectral property data of the compound, and discloses a new use of the compound in preparing a drug for preventing and / or treating infectious diseases caused by methicillin-resistant Staphylococcus aureus (MRSA) and other gram-positive drug-resistant bacteria. The in-vitro antibacterial experiment results show that a representative compound of the application has excellent antibacterial activity on MRSA strains and exhibits a unique ability of inhibiting biofilm formation.

This invention discloses the application of a combined acoustic / optical technology in enhancing the inhibitory effect of MOFs complexes on drug-resistant bacteria, belonging to the field of pharmaceutical technology. The MOFs complex is a composite material, ZIF-8@PDA, with ZIF-8 as the organic framework and PDA coated on its surface. This invention selected methicillin-resistant Staphylococcus aureus (MRSA) as the research object, and its inhibitory effect was measured by the acoustic / photodynamic activity of the material. The results show that the inhibitory effect of ZIF-8@PDA combined with acoustic / optical technology on drug-resistant bacteria is significantly better than that of ZIF-8@PDA complex alone under light irradiation or ultrasound alone. This method, as a potential antibacterial approach, has certain guiding significance for clinical inhibition of drug-resistant bacterial infections.

The present invention belongs to the medical field, and relates to novel β-lactamase inhibitors, for the treatment of bacterial infections in combination with β-lactam antibiotics, including infection caused by drug resistant organisms and especially multi-drug resistant organisms. The present invention includes compounds according to formula (I) : or pharmaceutically acceptable salts thereof, wherein M and X are as defined herein.

The application discloses a metabolite preparation for relieving intestinal inflammation and an application and use method thereof, and relates to the technical field of metabolite preparations.The metabolite preparation for relieving intestinal inflammation is selected to realize specific and efficient relief of intestinal inflammation of farmed animals, improve intestinal tissue damage, and maintain intestinal physiological function homeostasis.The metabolite preparation for relieving intestinal inflammation avoids heavy metal residue and environmental pollution, guarantees the safety of livestock products, and meets the development needs of green breeding.The metabolite preparation for relieving intestinal inflammation relieves inflammation by regulating intestinal physiological function and repairing the intestinal barrier, does not directly inhibit or kill pathogenic bacteria, fundamentally eliminates the generation and spread of drug-resistant strains, and reduces public health safety hazards.

A method and apparatus for inhibiting bacterial biofilms using magnetically driven nanoparticles, belonging to the field of biomedical technology, addresses the problem of traditional antibiotics inhibiting bacterial biofilms. This method utilizes a magnetic field to drive the physical-mechanical movement of magnetic nanoparticles, synergistically inducing drug action, thus achieving better biofilm inhibition and is more suitable for eliminating drug-resistant bacteria. Furthermore, the designed apparatus for inhibiting bacterial biofilms using magnetically driven nanoparticles is small, easy to use, and highly practical. Compared to traditional antibiotics, this technology, combined with superparamagnetic nanoparticles, can be applied to wound healing, possessing significant commercial value.

Turbinmicin, an isolated compound of Formula I or IA is provided. Turbinomycin compounds of Formula II or IIA are also provided. A compound isolated from a bacterial species from the sea squirt, Ecteinascidia turbinate, and having a chemical formula of C34H29NO11 is also provided. Compositions including turbinmicin and turbinmicin compounds, such as pharmaceutical compositions including effective amounts of turbinmicin or turbinomicing compounds for treating fungal infections such as Candida and Aspergillus, including drug-resistant strains thereof, are also disclosed. Methods of treating fungal infections with turbinmicin, turbinmicin compounds and compositions thereof are disclosed.

The present invention relates to antibiotic-resistant bacteria, and to the prevention or treatment of infections of drug-resistant pathogens, such as carbapenem-resistant Enterobacteriaceae (CRE) and / or vancomycin-resistant Enterococcus (VRE). In particular, the invention relates to the treatment or prevention of colonisation of CRE and / or VRE in the gastrointestinal (GI) tract, before they cause invasive infections, for example in the blood. The invention provides novel formulations, pharmaceutical compositions and methods of using them to prevent or treat CRE and / or VRE infections or intestinal colonisations thereof.

The application discloses application of arundine and the antibiotic in preparation of a medicine for treating a bacterial infectious disease. The arundine has synergistic activity with a plurality of antibiotics in vivo and in vitro, and the combined use has strong bacteriostatic and bactericidal activity on a plurality of drug-resistant bacteria. The effectiveness in vivo and in vitro, the stability and the safety are systematically evaluated, which is helpful to develop a new type of antibiotic adjuvant candidate for resisting multiple drug-resistant bacteria, and to relieve the problem of the increasingly serious multiple drug-resistant bacteria (MDR).

This invention belongs to the field of biomedical technology and discloses an α-hemolysin inhibitor and its application in the preparation of anti-infective drugs for Staphylococcus aureus. The inhibitor is mangiferin, and its novel use as a small molecule inhibitor of Staphylococcus aureus α-hemolysin (Hla) and related drug preparation methods are described. This invention, through in vitro hemolysis experiments, Hla protein purification and inhibitory activity verification, binding stability experiments, molecular docking studies, and in vivo animal experiments, confirms that mangiferin can efficiently and directly inhibit the hemolytic activity of Staphylococcus aureus supernatant and purified Hla protein in a dose-dependent manner; it can form a stable complex with Hla protein through hydrogen bonds and other interactions, blocking the pore-breaking activity of Hla in an irreversible or high-affinity binding manner, with a long-lasting inhibitory effect. This invention provides a novel candidate drug and technical solution for solving the problems of Staphylococcus aureus (including drug-resistant strains) infection and antibiotic resistance, with broad application prospects.

The application belongs to the technical field of medicine, and discloses application of genistein in preparation of medicine for resisting Mycobacterium tuberculosis. The application discloses application of genistein or a pharmaceutically acceptable derivative thereof in inhibition of Mycobacterium tuberculosis or preparation of products for resisting Mycobacterium tuberculosis. Experiments show that the MIC of genistein to M. tb H37Rv ΔleuΔpan and M. tb M. tb M. tb M. tb M. tb H37Ra is 0.03 mg / mL, and under the action of 30 μg / mL genistein, the minimum inhibitory concentration of a rifampicin-resistant strain is reduced from 50 μg / mL to 6.25 μg / mL, which greatly improves the sensitivity of the drug-resistant strain to rifampicin. Therefore, genistein can be used in preparation of medicine for resisting Mycobacterium tuberculosis or resisting tuberculosis alone, and can also be used as an auxiliary medicine for other anti-tuberculosis medicines for combined use, that is, the types of anti-tuberculosis medicines are widened and the course of treatment of tuberculosis is expected to be shortened.